Entyvio 300 mg powder for concentrate for solution for infusion clinical trials
8 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to severe ulcerative colitis in adults
This study is looking at a new way to treat severe ulcerative colitis. It tests if adding oxygen therapy to existing biologic medicines works better than biologics alone to reduce symptoms like diarrhoea and blood in your poo, and improve gut healing.
For: Ulcerative colitisPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE)
This study compares a new medicine (PB016) with an existing one (Entyvio®) for adults with moderate to severe ulcerative colitis. It looks at how well they work to reduce symptoms and keep people well, as well as their safety.
For: ulcerative colitisCzechia · Poland · Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease Long-term Safety With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease.
This study looks at the long-term safety of a medicine called Entyvio for children and young people with Crohn's disease or ulcerative colitis. It aims to see how safe the treatment is over time and if it causes any side effects.
For: Ulcerative Colitis or Crohn's DiseaseHungary · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
This study looks at a medicine called Entyvio for children and teenagers with moderate to severe ulcerative colitis. It aims to see if Entyvio helps them stay in remission (when symptoms improve or disappear) and if it's safe to use over time.
For: Moderately to severely active Ulcerative Colitis (UC)Greece · Croatia · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis
This study is comparing two medicines, AVT16 and Entyvio, for people aged 18-80 with moderate to severe ulcerative colitis. It will check how well they work, how safe they are, and how the body reacts to them over 52 weeks. The main goal is to see if symptoms improve after 6 weeks.
For: Moderate to Severe Active Ulcerative ColitisCroatia · Latvia · Slovakia - AuthorisedPhase III and phase IV (Integrated)
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
This study looks at how certain medicines for ulcerative colitis might affect heart and blood vessel health. We want to see if these treatments change the thickness of neck artery walls or how stiff the main heart artery is in people with ulcerative colitis.
For: ulcerative colitisFrance - Ongoing, recruitingTherapeutic use (Phase IV)
VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target
This study, called VERDICT, looks at how best to treat ulcerative colitis. It compares different treatment goals using Entyvio, a common medication. The main aim is to see which treatment approach helps patients avoid colitis-related problems for the longest time.
For: Ulcerative colitisItaly · Belgium · France - AuthorisedTherapeutic use (Phase IV)
Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial
This study looks at how well a treatment called faecal microbiota transplant (FMT) works with other medicines (infliximab and vedolizumab) for people with ulcerative colitis. The aim is to see if this combination helps people feel better and stay in remission without needing steroids.
For: Ulcerative Colitis · Crohn´s diseaseFinland